Product Description
ERGOCALCIFEROL (er goe kal SIF e role) is a man made form of vitamin D. It helps your body keep the right amount of calcium and phosphorus for healthy bones and teeth. (Sourced from: https://my.clevelandclinic.org/health/drugs/19456-ergocalciferol-vitamin-d2-tablets-or-capsules)
Mechanisms of Action: VDR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Serbia | Slovakia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Vitamin D Deficiency | Vitamin D Deficiency
Known Adverse Events: Diplopia | Dizziness | Headache | Erythema | Pruritus | Angioedema | Urticaria | Anaphylaxis | Edema
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Hungary, Italy, Singapore, Spain
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Leiomyoma|Melanoma|Myocardial Infarction|Myofibroma|Sarcopenia
Phase 2: Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| D-ECISIVE | P3 |
Not yet recruiting |
Sarcopenia |
2025-12-31 |
|
| DELPHYS PLUS | P3 |
Recruiting |
Myofibroma|Leiomyoma |
2025-07-01 |
66% |
| DELPHYS PLUS | P3 |
Recruiting |
Myofibroma|Leiomyoma |
2025-07-01 |
66% |
| DELPHYS PLUS | P3 |
Recruiting |
Myofibroma|Leiomyoma |
2025-07-01 |
66% |
| DELPHYS PLUS | P3 |
Recruiting |
Myofibroma|Leiomyoma |
2025-07-01 |
66% |
| ACTRN12622001576718 | P2 |
Not yet recruiting |
Alzheimer Disease |
2024-06-01 |
|
| VITDAMI | P3 |
Completed |
Myocardial Infarction |
2023-05-01 |